Japan Study To Investigate New Nivolumab Combo
This article was originally published in PharmAsia News
Executive Summary
The efficacy promise presented by combinations of new cancer immunotherapies was a major factor behind Pfizer's recent major alliance with Merck Kgaa. On a smaller scale, it is now the driving force behind a planned clinical study in Japan with a first-in-class PD-1 inhibitor.